Product
Sofosbuvir + Velpatasvir
Aliases
Epclusa
Name
Epclusa
INN Name
Velpatasvir and Sofosbuvir
FDA Approved
Yes
6 clinical trials
1 organization
8 indications
1 document
Indication
Hepatitis C Virus InfectionIndication
Hepatitis CIndication
ChronicIndication
Infections during pregnancyIndication
RDTIndication
Opioid-Related DisordersIndication
Injection Drug UseIndication
Kidney TransplantClinical trial
A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection TrialsStatus: Terminated, Estimated PCD: 2023-01-06
Clinical trial
Safety, Tolerability, and Outcomes of Velpatasvir/SofosbuviR in Treatment of Chronic Hepatitis C Virus During Pregnancy (STORC)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania (CUTTS HepC): a Non-randomised, Quasiexperimental, Prospective Comparative TrialStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Same-visit Hepatitis C Testing and Treatment to Accelerate Cure Among People Who Inject Drugs: a Cluster Randomised Control Trial (The QuickStart Study)Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: The Kentucky Viral Hepatitis Treatment (KeY Treat) StudyStatus: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
An Open Label, Proof of Concept Study to Evaluate the Feasibility and Safety of Kidney Transplant From HCV Positive Donors Into HCV Negative RecipientStatus: Completed, Estimated PCD: 2021-04-28
Document
DailyMed Label: EpclusaOrganization
Gilead Sciences, Inc.